Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/Beta-Thalassemia, sickle cell/Hemoglobin C disease and severe combined immunodeficiency costs and cost analysis
This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, s...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Edmonton, AB, Canada
Institute of Health Economics
2016, March 2016
|
| Series: | Alberta STE report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting |
|---|---|
| Physical Description: | 1 PDF file (xxviii, 256 pages) illustrations |
| ISBN: | 9781926929651 |